Showing results (1-10 of 58) with videos related to

Sort By:
Pageof 6
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 12, 2013
[T-DM1 and pertuzumab: emerging anti-HER2 therapeutics]Emi Noguchi, Chikako Shimizu
Gan to Kagaku Ryoho. Cancer & Chemotherapy|November 16, 2011
[Chemotherapy-induced peripheral neuropathy]Emi Noguchi, Yoshiharu Maeda
Japanese Journal of Clinical Oncology|December 16, 2020
Current status of PD-1/PD-L1 blockade immunotherapy in breast cancerEmi Noguchi, Tadahiko Shien, Hiroji Iwata
JCO Oncology Practice|September 21, 2020
Safety and Evidence of Off-Label Use of Approved Drugs at the National Cancer Center Hospital in JapanSeiko Bun, Kan Yonemori, Hiroko Sunadoi, et al.
Cancers|April 3, 2021
Breast Cancer Brain Metastasis-Overview of Disease State, Treatment Options and Future PerspectivesChikashi Watase, Sho Shiino, Tatsunori Shimoi, et al.
Breast Cancer (Tokyo, Japan)|July 25, 2018
Trastuzumab emtansine plus pertuzumab in Japanese patients with HER2-positive metastatic breast cancer: a phase Ib studyEmi Noguchi, Kenji Tamura, Masaya Hattori, et al.
Cancer Chemotherapy and Pharmacology|June 7, 2018
Efficacy of capecitabine in patients with locally advanced or metastatic breast cancer with or without prior treatment with fluoropyrimidine: a retrospective studySakura Iizumi, Akihiko Shimomura, Tatsunori Shimoi, et al.
BMC Cancer|March 21, 2021
Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective studyRui Kitadai, Tatsunori Shimoi, Kazuki Sudo, et al.
International Journal of Clinical Oncology|September 1, 2021
Clinical management and outcomes associated with etoposide, doxorubicin, and cisplatin plus mitotane treatment in metastatic adrenocortical carcinoma: a single institute experienceMasaki Uchihara, Maki Tanioka, Yuki Kojima, et al.
Cancer Treatment and Research Communications|June 13, 2022
Case report: Response to platinum agents and poly (adenosine diphosphate-ribose) polymerase inhibitor in a patient with BRCA1 c.5096G>A (R1699Q) intermediate-risk variantAyumi Saito, Maki Tanioka, Makoto Hirata, et al.
Pageof 6